AmerisourceBergen completes acquisition of PharmaLex

AmerisourceBergen has completed its €1.28 billion acquisition of PharmaLex, a global healthcare and life sciences consulting and outsourcing service provider.

The acquisition expands AmerisourceBergen’s geographic reach and enhances its global portfolio of solutions to support partners across the pharmaceutical development and commercialization journey.

PharmaLex is a global team of scientific, regulatory, and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a product’s lifecycle.

Headquartered in Germany, PharmaLex has global reach, with a significant footprint in Europe and the U.S. and a growing presence in other parts of the world. PharmaLex’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services complement AmerisourceBergen’s current portfolio of commercialization solutions, which includes market access, patient services and reimbursement support.

Willis Chandler, president of Global Pharma Services, AmerisourceBergen, said: “As our partners continue to drive innovation in healthcare, we remain focused on delivering best-in-class support across the development and commercialization journey to help them maximize commercial success and increase patient access.

“PharmaLex’s significant global reach and end-to-end capabilities, coupled with our portfolio of commercialization solutions and distribution capabilities, will allow us to provide our partners with enhanced support and value across the product lifecycle. Together we will expand on each other’s capabilities to deliver an industry leading customer experience and help our partners achieve the outcomes they desire.”

Thomas Dobmeyer, CEO and managing partner, PharmaLex, said: “The opportunity to join AmerisourceBergen is a positive step forward for PharmaLex and extends the value and support we can provide our partners as they look to bring products to market.

“Our clients will now have access to a more robust and expansive suite of global solutions and services that can be tailored to meet their specific needs at any point in the product lifecycle – from taking a product through clinical trials to pharmaceutical distribution and accelerating patient access to prescribed medication. We look forward to working with our new colleagues and building on each other’s capabilities as we pursue our shared commitment of creating healthier futures.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news